RxSight Faces Class Action Lawsuit Over Securities Violations
PorAinvest
lunes, 22 de septiembre de 2025, 3:49 am ET1 min de lectura
RXST--
The complaint alleges that RxSight violated §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by making materially false and misleading statements about its business, operations, and prospects. According to the lawsuit, the company overstated customer demand for its products and failed to disclose significant adoption challenges and structural issues that led to declining sales and utilization rates. These misrepresentations caused investors to suffer damages when the market learned the truth about RxSight's financial condition [1].
The class action lawsuit has been filed by the Schall Law Firm, a national shareholder rights litigation firm, and investors are encouraged to join by contacting Brian Schall at the Schall Law Firm. The firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation [1].
Another law firm, Bronstein, Gewirtz & Grossman, LLC, has also announced that it is seeking investors who suffered substantial losses to lead a class action lawsuit against RxSight. The firm alleges that the company made materially false and misleading statements and failed to disclose material adverse facts about its business. Investors are encouraged to contact Peretz Bronstein or Nathan Miller at Bronstein, Gewirtz & Grossman, LLC to discuss their potential participation in the lawsuit [2].
Both law firms have set a deadline of September 22, 2025, for investors to contact them and discuss their potential participation in the lawsuit. The class, in this case, has not yet been certified, and until certification occurs, investors are not represented by an attorney. If investors choose to take no action, they can remain an absent class member [1].
Investors who wish to review a copy of the Complaint can visit the respective firm's website or contact the firm directly for more information. The Schall Law Firm can be reached at 310-301-3335, while Bronstein, Gewirtz & Grossman, LLC can be reached at 332-239-2660 [1][2].
A class action lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) for alleged securities violations between November 7, 2024 and July 8, 2025. Investors who purchased the company's securities during this period are encouraged to contact the Schall Law Firm before September 22, 2025. The lawsuit alleges violations of the Securities Exchange Act of 1934 and Rule 10b-5.
A class action lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) for alleged securities violations between November 7, 2024 and July 8, 2025. The lawsuit, brought by the Schall Law Firm, accuses the company of making false and misleading statements regarding its business operations and financial prospects. Investors who purchased the company's securities during this period are encouraged to contact the Schall Law Firm before September 22, 2025, to discuss their potential participation in the lawsuit [1].The complaint alleges that RxSight violated §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by making materially false and misleading statements about its business, operations, and prospects. According to the lawsuit, the company overstated customer demand for its products and failed to disclose significant adoption challenges and structural issues that led to declining sales and utilization rates. These misrepresentations caused investors to suffer damages when the market learned the truth about RxSight's financial condition [1].
The class action lawsuit has been filed by the Schall Law Firm, a national shareholder rights litigation firm, and investors are encouraged to join by contacting Brian Schall at the Schall Law Firm. The firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation [1].
Another law firm, Bronstein, Gewirtz & Grossman, LLC, has also announced that it is seeking investors who suffered substantial losses to lead a class action lawsuit against RxSight. The firm alleges that the company made materially false and misleading statements and failed to disclose material adverse facts about its business. Investors are encouraged to contact Peretz Bronstein or Nathan Miller at Bronstein, Gewirtz & Grossman, LLC to discuss their potential participation in the lawsuit [2].
Both law firms have set a deadline of September 22, 2025, for investors to contact them and discuss their potential participation in the lawsuit. The class, in this case, has not yet been certified, and until certification occurs, investors are not represented by an attorney. If investors choose to take no action, they can remain an absent class member [1].
Investors who wish to review a copy of the Complaint can visit the respective firm's website or contact the firm directly for more information. The Schall Law Firm can be reached at 310-301-3335, while Bronstein, Gewirtz & Grossman, LLC can be reached at 332-239-2660 [1][2].
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios